Global Parathyroid Disorders Market to Reach USD 3,197.02 Million by 2032 | CAGR of 5.8%
Category : Healthcare | Published Date : Jan 2025 | Type : Press Release
Parathyroid Disorders Market Scope & Overview:
In the newly published report, Consegic Business Intelligence states that the Parathyroid Disorders Market was valued at USD 2,036.48 million in 2024 and is projected to grow at a CAGR of 5.8%, reaching USD 3,197.02 million by 2032. Parathyroid disorders involve conditions that affect the parathyroid glands, including hyperparathyroidism, hypoparathyroidism, and parathyroid cancer, which disrupt calcium and phosphate balance in the body. The market comprises diagnostic tools, surgical treatments, hormone replacement therapies, and medications designed to manage these conditions. Rising awareness about endocrine health, advancements in diagnostic technologies, and the development of targeted therapies are driving market growth.
The report comprises the Parathyroid Disorders Market Share, Size & Industry Analysis, based on Type (Hyperparathyroidism, Hypoparathyroidism), Diagnosis (Blood Tests, Imaging Tests, Bone Density Tests), Treatment (Medications, Surgery, Hormone Replacement Therapy, Dietary Management), End-User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Homecare Settings), and Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), and Forecast, 2025–2032.
The report contains detailed information on Parathyroid Disorders Market Trends, Opportunities, Value, Growth Rate, Segmentation, Geographical Coverage, Company Profiles, In-depth Expert Analysis, Revenue Forecast, Competitive Landscape, Growth Factors, Restraints or Challenges, Environment & Regulatory Landscape, PESTLE Analysis, PORTER Analysis, Key Technology Landscape, Value Chain Analysis, and Cost Analysis.
Segmental Analysis :
Based on type, the market is segmented into Hyperparathyroidism and Hypoparathyroidism.
- Hyperparathyroidism accounted for the largest market share in 2024, driven by its high prevalence globally, particularly due to chronic kidney disease and calcium imbalances. Advancements in minimally invasive parathyroidectomy procedures have improved treatment outcomes.
- Hypoparathyroidism is projected to grow at the fastest CAGR due to growing research in recombinant parathyroid hormone therapies and increasing awareness of calcium and phosphate balance management.
Based on diagnosis, the market is segmented into Blood Tests, Imaging Tests, and Bone Density Tests.
- Blood Tests dominated the market in 2024 as they are the first-line diagnostic tool for assessing calcium and parathyroid hormone (PTH) levels. Their affordability, simplicity, and widespread availability contribute to their dominant share.
- Imaging Tests are expected to grow at the fastest rate, driven by the rising use of advanced modalities like 4D CT scans and MRIs for accurate localization of abnormal parathyroid glands.
Based on treatment, the market is segmented into Medications, Surgery, Hormone Replacement Therapy, and Dietary Management.
- Medications held the largest share in 2024 due to the increasing use of calcium supplements, vitamin D analogs, and phosphate binders for managing parathyroid disorders.
- Hormone Replacement Therapy is projected to grow at the fastest CAGR, supported by the adoption of recombinant parathyroid hormone therapies for chronic hypoparathyroidism and the expansion of advanced treatment options.
Based on end-user, the market is segmented into Hospitals, Specialty Clinics, Ambulatory Surgical Centers, and Homecare Settings.
- Hospitals accounted for the largest revenue share of 38.90% in 2024, driven by their role in offering comprehensive diagnostics, advanced surgical procedures, and long-term management for parathyroid disorders.
- Specialty Clinics are anticipated to grow at the fastest rate, fueled by the increasing demand for specialized care and personalized treatment approaches for chronic endocrine disorders.
Based on regions, the market is segmented into North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America.
- North America led the market in 2024, valued at USD 675.52 million, with the U.S. holding a 74.50% share due to its advanced healthcare infrastructure, high awareness of endocrine disorders, and adoption of innovative treatment solutions.
- Asia-Pacific is expected to grow at the fastest CAGR of 6.2%, driven by rising healthcare investments, growing awareness of endocrine health, and advancements in diagnostic capabilities across China, India, and Japan.
| Report Attributes | Report Details |
| Study Timeline | 2019-2032 |
| Market Size in 2032 | USD 3,197.02 Million |
| CAGR (2025-2032) | 5.8% |
| Type | Hyperparathyroidism (Primary, Secondary, Tertiary), Hypoparathyroidism |
| Diagnosis | Blood Tests, Imaging Tests, Bone Density Tests |
| Treatment | Medications, Surgery, Hormone Replacement Therapy, Dietary Management |
| End-User | Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Homecare Settings |
| By Region | North America(U.S., Canada, Mexico) Europe(U.K., Germany, France, Spain, Italy, Russia, Benelux, Rest of Europe) APAC(China, South Korea, Japan, India, Australia, ASEAN, Rest of Asia-Pacific) Middle East & Africa(GCC, Turkey, South Africa, Rest of MEA) LATAM(Brazil, Argentina, Chile, Rest of LATAM) |
Top Key Players & Competitive Landscape :
The competitive landscape encompasses major innovators, aftermarket service providers, industry giants, and niche players, all of which are thoroughly examined by Consegic Business Intelligence in terms of their strengths, weaknesses, and value-addition potential. This report includes detailed profiles of key players, market share analysis, mergers and acquisitions, resulting market fragmentation, and emerging partnership trends and dynamics.
List of prominent players in the Parathyroid Disorders Industry:
- Amgen Inc. (United States)
- Takeda Pharmaceutical Company Limited (Japan)
- Shire (part of Takeda Pharmaceutical Company) (Ireland)
- Roche Holding AG (Switzerland)
- Sanofi S.A. (France)
- Novartis AG (Switzerland)
- Pfizer Inc. (United States)
- Ascendis Pharma A/S (Denmark)
- Kyowa Kirin Co., Ltd. (Japan)
- Amryt Pharma (Ireland)
Recent Industry Developments :
- August 2024: Ascendis Pharma received U.S. FDA approval for Yorvipath, a once-daily therapy for adult hypoparathyroidism patients, eliminating the need for daily vitamin D and calcium supplements.
- May 2023: Amgen Inc. expanded its parathyroid disorder portfolio by acquiring innovative calcium-sensing receptor modulators to improve hyperparathyroidism treatment.
- October 2023: Takeda Pharmaceuticals partnered with leading endocrinology centers to develop next-generation hormone replacement therapies for hypoparathyroidism.
